Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient
Highlights • Afatinib is a tyrosine kinase inhibitor for first-line therapy in advanced non-small cell lung cancer. • Stevens-Johnson syndrome related to EGFR directed tyrosin kinase inhibitors as a rare adverse event. • first case report of SJS during afatinib treatment
Gespeichert in:
| Veröffentlicht in: | Lung cancer (Amsterdam, Netherlands) Netherlands), 2016-05, Vol.95, p.35-38 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 38 |
|---|---|
| container_issue | |
| container_start_page | 35 |
| container_title | Lung cancer (Amsterdam, Netherlands) |
| container_volume | 95 |
| creator | Doesch, Janine Debus, Dirk Meyer, Christian Papadopoulos, Thomas Schultz, Erwin S Ficker, Joachim H Brueckl, Wolfgang M |
| description | Highlights • Afatinib is a tyrosine kinase inhibitor for first-line therapy in advanced non-small cell lung cancer. • Stevens-Johnson syndrome related to EGFR directed tyrosin kinase inhibitors as a rare adverse event. • first case report of SJS during afatinib treatment |
| doi_str_mv | 10.1016/j.lungcan.2016.02.015 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1778705780</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0169500216302318</els_id><sourcerecordid>1778705780</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-fc86c47297acae500afaee899d33ca71937e1da5dd874b8018b89e8676aedb533</originalsourceid><addsrcrecordid>eNqFkUFv1DAQhS0EokvLTyjKkUvC2E5i5wKqqraAKiGx9Gw59qR4SezFTirtv8dhFw5cOFmW33vz_A0hlxQqCrR9t6vGxT8a7SuWrxWwCmjzjGyoFKyUnLPnZJMfurIBYGfkVUo7ACoodC_JGRNQg6y7DdleDXp23vWlTikYp2e0xXbGJ_Sp_By--xR8kQ7exjBh4XyhfXFzd_u1nJb5t3ZtUeQaBmOxz1Ho5wvyYtBjwten85w83N58u_5Y3n-5-3R9dV-amsFcDka2phasE9pozDX1oBFl11nOjRa04wKp1Y21UtS9BCp72aFsRavR9g3n5-TtMXcfw88F06wmlwyOo_YYlqSoEFJAIyRkaXOUmhhSijiofXSTjgdFQa081U6deKqVpwKmMs_se3MasfQT2r-uPwCz4MNRgPmjTw6jSiYzMGhdRDMrG9x_R7z_J8GMeSFGjz_wgGkXlugzRUVVyga1XZe67pS2HBinkv8CD52ejQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1778705780</pqid></control><display><type>article</type><title>Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Doesch, Janine ; Debus, Dirk ; Meyer, Christian ; Papadopoulos, Thomas ; Schultz, Erwin S ; Ficker, Joachim H ; Brueckl, Wolfgang M</creator><creatorcontrib>Doesch, Janine ; Debus, Dirk ; Meyer, Christian ; Papadopoulos, Thomas ; Schultz, Erwin S ; Ficker, Joachim H ; Brueckl, Wolfgang M</creatorcontrib><description>Highlights • Afatinib is a tyrosine kinase inhibitor for first-line therapy in advanced non-small cell lung cancer. • Stevens-Johnson syndrome related to EGFR directed tyrosin kinase inhibitors as a rare adverse event. • first case report of SJS during afatinib treatment</description><identifier>ISSN: 0169-5002</identifier><identifier>EISSN: 1872-8332</identifier><identifier>DOI: 10.1016/j.lungcan.2016.02.015</identifier><identifier>PMID: 27040849</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Adrenal Cortex Hormones - therapeutic use ; Afatinib ; Aged ; Female ; Hematology, Oncology and Palliative Medicine ; Humans ; Lung Neoplasms - complications ; Lung Neoplasms - diagnosis ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Mutation ; NSCLC ; Protein Kinase Inhibitors - adverse effects ; Pulmonary/Respiratory ; Quinazolines - adverse effects ; Receptor, Epidermal Growth Factor - genetics ; SJS ; Skin - pathology ; Stevens-Johnson Syndrome - diagnosis ; Stevens-Johnson Syndrome - drug therapy ; Stevens-Johnson Syndrome - etiology ; TKI ; Treatment Outcome</subject><ispartof>Lung cancer (Amsterdam, Netherlands), 2016-05, Vol.95, p.35-38</ispartof><rights>2016 Elsevier Ireland Ltd</rights><rights>Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-fc86c47297acae500afaee899d33ca71937e1da5dd874b8018b89e8676aedb533</citedby><cites>FETCH-LOGICAL-c420t-fc86c47297acae500afaee899d33ca71937e1da5dd874b8018b89e8676aedb533</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.lungcan.2016.02.015$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27040849$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Doesch, Janine</creatorcontrib><creatorcontrib>Debus, Dirk</creatorcontrib><creatorcontrib>Meyer, Christian</creatorcontrib><creatorcontrib>Papadopoulos, Thomas</creatorcontrib><creatorcontrib>Schultz, Erwin S</creatorcontrib><creatorcontrib>Ficker, Joachim H</creatorcontrib><creatorcontrib>Brueckl, Wolfgang M</creatorcontrib><title>Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient</title><title>Lung cancer (Amsterdam, Netherlands)</title><addtitle>Lung Cancer</addtitle><description>Highlights • Afatinib is a tyrosine kinase inhibitor for first-line therapy in advanced non-small cell lung cancer. • Stevens-Johnson syndrome related to EGFR directed tyrosin kinase inhibitors as a rare adverse event. • first case report of SJS during afatinib treatment</description><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>Afatinib</subject><subject>Aged</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Lung Neoplasms - complications</subject><subject>Lung Neoplasms - diagnosis</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Mutation</subject><subject>NSCLC</subject><subject>Protein Kinase Inhibitors - adverse effects</subject><subject>Pulmonary/Respiratory</subject><subject>Quinazolines - adverse effects</subject><subject>Receptor, Epidermal Growth Factor - genetics</subject><subject>SJS</subject><subject>Skin - pathology</subject><subject>Stevens-Johnson Syndrome - diagnosis</subject><subject>Stevens-Johnson Syndrome - drug therapy</subject><subject>Stevens-Johnson Syndrome - etiology</subject><subject>TKI</subject><subject>Treatment Outcome</subject><issn>0169-5002</issn><issn>1872-8332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUFv1DAQhS0EokvLTyjKkUvC2E5i5wKqqraAKiGx9Gw59qR4SezFTirtv8dhFw5cOFmW33vz_A0hlxQqCrR9t6vGxT8a7SuWrxWwCmjzjGyoFKyUnLPnZJMfurIBYGfkVUo7ACoodC_JGRNQg6y7DdleDXp23vWlTikYp2e0xXbGJ_Sp_By--xR8kQ7exjBh4XyhfXFzd_u1nJb5t3ZtUeQaBmOxz1Ho5wvyYtBjwten85w83N58u_5Y3n-5-3R9dV-amsFcDka2phasE9pozDX1oBFl11nOjRa04wKp1Y21UtS9BCp72aFsRavR9g3n5-TtMXcfw88F06wmlwyOo_YYlqSoEFJAIyRkaXOUmhhSijiofXSTjgdFQa081U6deKqVpwKmMs_se3MasfQT2r-uPwCz4MNRgPmjTw6jSiYzMGhdRDMrG9x_R7z_J8GMeSFGjz_wgGkXlugzRUVVyga1XZe67pS2HBinkv8CD52ejQ</recordid><startdate>20160501</startdate><enddate>20160501</enddate><creator>Doesch, Janine</creator><creator>Debus, Dirk</creator><creator>Meyer, Christian</creator><creator>Papadopoulos, Thomas</creator><creator>Schultz, Erwin S</creator><creator>Ficker, Joachim H</creator><creator>Brueckl, Wolfgang M</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160501</creationdate><title>Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient</title><author>Doesch, Janine ; Debus, Dirk ; Meyer, Christian ; Papadopoulos, Thomas ; Schultz, Erwin S ; Ficker, Joachim H ; Brueckl, Wolfgang M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-fc86c47297acae500afaee899d33ca71937e1da5dd874b8018b89e8676aedb533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>Afatinib</topic><topic>Aged</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Lung Neoplasms - complications</topic><topic>Lung Neoplasms - diagnosis</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Mutation</topic><topic>NSCLC</topic><topic>Protein Kinase Inhibitors - adverse effects</topic><topic>Pulmonary/Respiratory</topic><topic>Quinazolines - adverse effects</topic><topic>Receptor, Epidermal Growth Factor - genetics</topic><topic>SJS</topic><topic>Skin - pathology</topic><topic>Stevens-Johnson Syndrome - diagnosis</topic><topic>Stevens-Johnson Syndrome - drug therapy</topic><topic>Stevens-Johnson Syndrome - etiology</topic><topic>TKI</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Doesch, Janine</creatorcontrib><creatorcontrib>Debus, Dirk</creatorcontrib><creatorcontrib>Meyer, Christian</creatorcontrib><creatorcontrib>Papadopoulos, Thomas</creatorcontrib><creatorcontrib>Schultz, Erwin S</creatorcontrib><creatorcontrib>Ficker, Joachim H</creatorcontrib><creatorcontrib>Brueckl, Wolfgang M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Doesch, Janine</au><au>Debus, Dirk</au><au>Meyer, Christian</au><au>Papadopoulos, Thomas</au><au>Schultz, Erwin S</au><au>Ficker, Joachim H</au><au>Brueckl, Wolfgang M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient</atitle><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle><addtitle>Lung Cancer</addtitle><date>2016-05-01</date><risdate>2016</risdate><volume>95</volume><spage>35</spage><epage>38</epage><pages>35-38</pages><issn>0169-5002</issn><eissn>1872-8332</eissn><abstract>Highlights • Afatinib is a tyrosine kinase inhibitor for first-line therapy in advanced non-small cell lung cancer. • Stevens-Johnson syndrome related to EGFR directed tyrosin kinase inhibitors as a rare adverse event. • first case report of SJS during afatinib treatment</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>27040849</pmid><doi>10.1016/j.lungcan.2016.02.015</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0169-5002 |
| ispartof | Lung cancer (Amsterdam, Netherlands), 2016-05, Vol.95, p.35-38 |
| issn | 0169-5002 1872-8332 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1778705780 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adrenal Cortex Hormones - therapeutic use Afatinib Aged Female Hematology, Oncology and Palliative Medicine Humans Lung Neoplasms - complications Lung Neoplasms - diagnosis Lung Neoplasms - drug therapy Lung Neoplasms - genetics Mutation NSCLC Protein Kinase Inhibitors - adverse effects Pulmonary/Respiratory Quinazolines - adverse effects Receptor, Epidermal Growth Factor - genetics SJS Skin - pathology Stevens-Johnson Syndrome - diagnosis Stevens-Johnson Syndrome - drug therapy Stevens-Johnson Syndrome - etiology TKI Treatment Outcome |
| title | Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T07%3A02%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Afatinib-associated%20Stevens-Johnson%20syndrome%20in%20an%20EGFR-mutated%20lung%20cancer%20patient&rft.jtitle=Lung%20cancer%20(Amsterdam,%20Netherlands)&rft.au=Doesch,%20Janine&rft.date=2016-05-01&rft.volume=95&rft.spage=35&rft.epage=38&rft.pages=35-38&rft.issn=0169-5002&rft.eissn=1872-8332&rft_id=info:doi/10.1016/j.lungcan.2016.02.015&rft_dat=%3Cproquest_cross%3E1778705780%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1778705780&rft_id=info:pmid/27040849&rft_els_id=S0169500216302318&rfr_iscdi=true |